The U.S. Court of Appeals for the Federal Circuit waded into the CRISPR/Cas9 patent fray Monday as it heard argument in the University of California's appeal of a Patent Trial and Appeal Board (PTAB) ruling last year that the Broad Institute's development of the gene editing tool for use in eukaryotic cells did not interfere with the university's patent.